Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
7.75
+0.43 (5.87%)
At close: Nov 6, 2026, 4:00 PM EST
7.64
-0.11 (-1.42%)
After-hours: Nov 6, 2026, 7:30 PM EST
Immunic Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
100
Market Cap
105.74M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Black Diamond Therapeutics | 70.00M |
| Equillium | 4.39M |
| NRx Pharmaceuticals | 3.39M |
| Milestone Pharmaceuticals | 2.34M |
| Kazia Therapeutics | 1.27M |
IMUX News
- 2 days ago - Immunic Transcript: R&D Day 2026 - Transcripts
- 2 days ago - Immunic Slides: FY 2026 - Filings
- 5 days ago - Immunic to Participate in Investor Conferences in November - PRNewsWire
- 9 days ago - Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026 - PRNewsWire
- 15 days ago - Immunic initiated with an Overweight at Cantor Fitzgerald - TheFly
- 15 days ago - Immunic initiated with an Overweight at Cantor Fitzgerald - TheFly
- 17 days ago - Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting - PRNewsWire
- 19 days ago - Immunic Slides: Investor presentation - Filings